MoonLake Immunotherapeutics (MLTX) Earnings History
Annual and quarterly earnings data from 2020 to 2025
Loading earnings history...
MLTX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
MLTX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export MLTX earnings history in CSV or JSON format
Free sign-in required to download data
MoonLake Immunotherapeutics (MLTX) Earnings Overview
As of May 8, 2026, MoonLake Immunotherapeutics (MLTX) reported trailing twelve-month net income of -$227M, reflecting -86.8% year-over-year growth. The company earned $-3.53 per diluted share over the past four quarters.
Looking at the long-term picture, MLTX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$90,838 in fiscal 2020.
MoonLake Immunotherapeutics is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including UCB ($328M net income, 21.4% margin), NKTR (-$164M net income, -297.1% margin), ARQT (-$2M net income, -4.3% margin), MLTX has comparable earnings metrics. Compare MLTX vs UCB →
MLTX Earnings vs Peers
Earnings metrics vs comparable public companies
MLTX Historical Earnings Data (2020–2025)
6 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$227M | -91.1% | -$245M | $-3.53 | - | - |
| 2024 | -$119M | -230.3% | -$143M | $-1.89 | - | - |
| 2023 | -$36M | +27.9% | -$54M | $-0.73 | - | - |
| 2022 | -$50M | +6.8% | -$65M | $-2.20 | - | - |
| 2021 | -$54M | -58954.2% | -$54M | $-1.45 | - | - |
| 2020 | $-90,838 | - | $-105,755 | $-0.01 | - | - |
See MLTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MLTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MLTX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonMLTX — Frequently Asked Questions
Quick answers to the most common questions about buying MLTX stock.
Is MLTX growing earnings?
MLTX EPS fell to $-3.53, with earnings declining -86.8%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-227M.
What are MLTX's profit margins?
MoonLake Immunotherapeutics net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are MLTX's earnings?
MLTX earnings data spans 2020-2025. The declining earnings trend is -86.8% YoY. Historical data enables comparison across business cycles.